111In-cetuximab-F(ab’)2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

“…In this study the fragments showed significantly lower uptake in the tumor, but lower uptake in the liver could not be observed, it was even higher within the first 4 h after administration. In addition, more radioactivity was measured in the kidney [159]. In a first clinical imaging study in patients with lung squamous cell carcinoma 111 In-DTPA-MAb225, the murine forerunner of cetuximab, also showed a high liver accumulation [98].…”

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab′)2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

“…In previous work, a preclinical SPECT tracer, 111 In-cetuximab-F(ab9) 2 , which can visualize the EGFR in HNSCC xenografts, was developed (22,23). Of these xenografts, responsiveness was evaluated designating SCCNij202 as sensitive and SCCNij167 as resistant, showing high tracer versus low tracer uptake, respectively (14).…”

111In-Cetuximab-F(ab′)2 SPECT and 18F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model

“…In previous studies, an anti-EGFR tracer, 111 In-cetuximab-F(ab9) 2 , was developed and evaluated in several preclinical setups. It has been shown to visualize systemically accessible EGFR in multiple HNSCC models and the change in accessible EGFR in response to singledose irradiation (13,14). Here, we assess its potential relevance in 2 HNSCC xenograft models and include 3 treatment arms-irradiation, cetuximab, and combination therapy-to evaluate its predictive value and its role in response monitoring.…”